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Summary The morphological appearance, incidence and prognostic significance of human chorionic
gonadotrophin (HCG)-containing cells in seminomas were examined in a retrospective series of 228
orchidectomy specimens, obtained between 1958 and 1972. Sections from each tumour were stained with
haematoxylin and eosin (H & E) and immunocytochemically for HCG. In 33 (14.5%) of the tumours HCG-
containing cells were observed, but in only 12 were these recognised in an initial study of the H & E stained
sections. HCG staining was seen predominantly in syncytiotrophoblastic giant cells and rarely in "mulberry"
cells and mononuclear seminoma cells. Of the patients whose tumours included HCG-containing cells 23%
died of their disease within 2 years of orchidectomy, compared with only 8% of the patients whose tumours
lacked this feature. It is concluded that immunocytochemical staining for HCG should form part of the
routine histological assessment of seminomas, and that the presence of HCG-containing cells indicates a more
aggressive disease.
It is established that patients with testicular
seminomas have a better prognosis than those with
malignant teratomas or neoplasms containing both
elements (Pugh, 1976). The teratomatous element in
a combined neoplasm may include extra-embryonic
elements in addition to somatic and un-
differentiated tumour tissue. However, when
solitary giant cells morphologically resembling
those in the syncytiotrophoblastic layer of the
placenta (Figure la) are found in seminomas it has
not been customary to classify these neoplasms as
combined tumours. There are two reasons for this
apparent paradox. Firstly, it was not certain that
all giant cells were trophoblastic in origin, as
various morphological forms of multinucleate cells
can be found in seminomas including the tumour
giant or "mulberry" cell (Thackray & Crane, 1976)
(Figure 2a) and the Langhans' giant cells (Figure 3)
associated with granulomata. Secondly, seminomas
with giant cells did not appear to pursue a more
malignant course and thus did not constitute a sub-
group within a prognostic classification (Thackray
& Crane, 1976; Peckham, 1981).
Since the advent of the immunoperoxidase
technique it has been possible-to localise human
chorionic gonadotrophin (HCG) in wax-embedded
tissue (Heyderman & Neville, 1976), and thus
syncytiotrophoblastic cells may be identified by
their HCG content. The cells defined by this
method may not prove always synonymous with
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the syncytiotrophoblastic giant cells (SGC)
characterised morphologically. It is therefore
appropriate to review the incidence and prognostic
significance of HCG-positive cells in seminomas.
Materials and methods
This retrospective study is based on tissue derived
from a series of 228 classical testicular seminomas,
received by the British Testicular Tumour Panel
and Registry from centres throughout Britain
during the period 1958-1972. The ages of the
patients ranged from 19-59 (average 40) years. In
each case between one and seven (average 3.4)
paraffin wax-embedded blocks oftumour tissue were
available. Survival data were available either for a
period of between 1 and 20 (average 8.4) years
following orchidectomy, or until death due to this
disease or another cause in all but 10 cases. The
tumours were classified as pathological stage P1
(tumour confined to the rete and body of testis), P2
(tumour spread into epididymis and/or lower cord)
or P3 (tumour spread into upper cord) (Thackray
& Crane, 1976).
The relationship between survival and the
presence of HCG-containing cells was analysed
only in P1 and P2 tumours, which had 3 year
survival rates of 93 and 92% respectively and were
thus considered to constitute a single prognostic
group, whereas P3 tumours had a 3 year survival
rate of 80% (Thackray & Crane, 1976). This series
of cases is consistent in terms of pathological
staging and treatment by orchidectomy for primary
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disease. However, because the patients presented at
centres throughout Britain over a long period, both
surgical staging and treatment for secondary disease
were not consistent, particularly in relation to the
quality and use of radiotherapy. Sufficient clinical
information was not available to analyse these
differences.
Sections from each block were stained with
haematoxylin and eosin (H & E) and immunocyto-
chemically for HCG with a peroxidase anti-
peroxidase (PAP) technique similar to that
described by Sternberger et al. (1970). Using
dewaxed sections endogenous peroxidase was
inhibited by a 10min incubation in freshly-prepared
0.5% hydrogen peroxide (BDH Chemicals
Ltd., Poole, Dorset, UK) in methanol (BDH
"Analar"). The sections were then incubated for
20min in freshly-prepared 0.1% beef pancreas
trypsin (BDH product number 39042) in 0.1%
aqueous calcium chloride (pH 7.8) at 37°C.
Following a 10min exposure to 20% normal swine
serum (Dakopatts, Mercia Brocades, West Byfleet,
Surrey, UK) the sections were incubated for 30min
at room temperature in rabbit anti-HCG serum
(provided by Professor K. Bagshawe, Department
of Medical Oncology, Charing Cross Hospital,
London) at a dilution of 1 in 600 in 1% bovine
serum albumin (Ortho Diagnostics Ltd., High
Wycombe, Buckinghamshire, UK) in Bacto FA
PBS, pH 7.2 (Difco Laboratories, West Molesey,
Surrey, UK). The swine anti-rabbit immuno-
globulins bridging antiserum was used at a
concentration of 1 in 100 for 30min, as was the
rabbit PAP complex (Dakopatts). Binding of these
antisera was demonstrated by a 5min exposure to
0.5mgml-1 3, 31-diaminobenzidine free base
(Sigma Ltd., Poole, Dorset, UK.) in PBS
containing 1 plml- 1 00 volumes hydrogen peroxide
(BDH). The sections were counter-stained with
Mayer's haematoxylin, dehydrated, cleared and
mounted in DPX (BDH). The specificity of the
primary antiserum was tested following its
absorption with ,B-HCG (World Health
Organisation 1st International Reference
Preparation, batch 75/551), which completely
blocked the staining reaction. Negative omission
and positive controls also were included to test the
specificity of the reaction.
The sections were assessed independently by two
observers (DB and MCP). Initially the H & E
preparations were examined for the presence of
SGC (Figure la). These cells have eosinophilic
"glassy" cytoplasm and frequently contain large
vacuoles incorporating red blood cells giving a
vasoformative appearance. Nuclei vary in number
and can be densely hyperchromatic or contain large
nucleoli. The occurrence of tumour giant cells
(mulberry cells) (Figure 2a) and Langhans' giant
cells (Figure 3) were noted. Cells containing HCG
were localised on immunocytochemical preparations
(Figures lb and 2b). The sections then were
compared to define, where possible, morphological
features associated with a positive or negative
reaction for HCG.
Results
HCG was localised in 33 of the 228 seminomas
(14.5%) and in 31 of these was present in SGC. In
12 of these cases SGC were seen on the initial
examination of the H & E section, but in 19
tumours SGC were appreciated only on review. In
the remaining 2 seminomas HCG was confined to
tumour giant cells or "mulberry" cells. In 5 of the
31 tumours with HCG-positive SGC, HCG was
present also in tumour giant cells (mulberry cells),
and mononuclear seminoma cells. Langhans' giant
cells were consistently negative for HCG.
The incidence of HCG-containing cells in
tumours of each pathological stage is shown in
Table I. Sampling error was difficult to exclude, but
the incidence was not related to the number of
blocks examined (Table II).
The relationship between the presence of HCG-
containing cells and survival in P1 and P2 tumours
Table I The incidence of HCG-containing
syncytiotrophoblastic cells in seminoma, in relation
to pathological stage
Pathological No. of No. of Incidence
stage tumours HCG +ve %
P1 119 18 15.1
P2 105 14 13.3
P3 4 1 25.0
Total 228 33 14.5
Table II Relationship between number of tissue
blocks available and incidence of HCG-containing
syncytiotrophoblastic cells
Proportion tumours
HCG-positive
No. ofavailable blocks (%)
1 1/5 (20)
2 2/24 (8)
3 17/102 (17)
4 8/74 (11)
5 5/13 (38)
6 0/9 (0)
7 0/1 (0)HCG LOCALIZATION IN SEMINOMA 475
Figure 1(a) Seminoma containing a syncytiotrophoblastic giant cell in the centre of the field (H & E x 150). (b) A section adjacent to (a), in which HCG is demonstrated in the syncytiotrophoblastic giant cell by an
immunoperoxidase technique (x 150).
Figure 2(a) "Mulberry" cell or tumour giant cell in a seminoma (H & E x400). (b) A section adjacent to (a)
in which HCG is demonstrated in the "mulberry" cell by an immunoperoxidase technique ( x400).
Figure 3 Langhans' giant cell associated with a
granulomatous reaction in a seminoma. HCG could
not be demonstrated in this cell by immunoperoxidase
technique. (H & E x 270).
is shown in Table III and Figure 4. Significantly
more of the patients with HCG-positive seminomas
died within 2 years of orchidectomy (P<0.01, chi-
square test with Yates' correction). However, no
further patients in this group died of this disease
more than two years after orchidectomy, in contrast
to the HCG-negative group, in whom relapse and
death occurred up to 10 years following
orchidectomy. Because of this difference in the
pattern of survival a log rank test (Peto & Pike,
1973) performed over the 15 year survival curves
was not significant (P=0.08), although it did show a
trend in favour of the HCG-negative group.
Comparing the survival before and after two years
post-orchidectomy demonstrates this difference
more clearly, since it shows a significant difference
(P<0.01) for survival up to two years in favour of
the HCG-negative group, but no significant
difference thereafter (P=0.3).
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Table III Relationship between the presence of HCG-
containing cells and survival in patients with pathological
stage P1 and P2 seminomas
HCG -ve HCG + ve
Dead Dead
No. Dead of Dead of
Follow-up of of other No. of of other
(yrs) patients disease cause patients disease cause
1 184 10 0 30 3 1
2 183 14 0 30 7 1
3 181 17 1 29 7 1
4 174 18 4 29 7 1
5 169 19 4 28 7 1
7 150 21 8 25 7 1
10 122 22 11 23 7 1
15 60 22 14 13 7 1
0F)
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improved and categories changed throughout the
period during which these tumours were
documented. Consequently, the results were related
to pathological stage for which information was
available and definitions had remained the same,
rather than clinical assessment of disease extent.
Despite these limitations this study is of clinical
relevance because it addresses the question of
whether the presence of HCG-containing cells
influences survival in the largest series of
seminomas available with a long follow-up. The
information obtained is of especial value if
surveillance rather than active therapy is considered
post orchidectomy for patients with clinical stage I
disease (Oliver et al., 1983). The identification of
HCG-positive cells as a poor prognostic factor may
contraindicate withholding treatment in these
patients.
Three aspects of HCG-containing cells in
seminomas were studied: their morphology,
incidence and prognostic significance.
Morphology
l_________________________________ Giant cells and multinucleate cells resembling
(29) (28) (25) (23) HCG + VE (13) syncytiotrophoblasts are an established morpho-
logical feature of some seminomas, the first
description being attributed to Chevassu in 1906
P= 0.08. (Hedinger et al., 1979), but their definition and
incidence in different series have varied (Friedman
& Moore, 1946; Dixon & Moore, 1952; Friedman
& Pearlman, 1970; Mostofi & Price, 1973;
Thackray & Crane, 1976). Some studies include all
giant cells except the Langhans cell, whereas others
confined themselves to the typical syncytiotropho-
3 6 9 12 15 blast. Furthermore, the methods of sampling and
Time (y) case selection differ in these studies.
The functional significance of these cells was Cumulative survival curves of 184 patients
CG-negative seminomas and 30 with HCG- partially resolved in 1976 when Heyderman and
seminomas, stages P1 and P2. The figures in Neville localised HCG in solitary giant cells in
sis indicate the total number ofpatients in the germ cell tumours. Since this time HCG in
)sitive and negative groups followed-up at each seminomas has been reported variously as occuring
Following orchidectomy (details are shown in exclusively in isolated cells or clusters of cells
I). showing the morphological features of syncytio-
trophoblasts (Javadpour et al., 1978; Kurman et al.,
1979; Mostofi, 1980), or to be localised commonly
in these cells and occasionally seen in seminoma
In giant cells ("mulberry" cells) (Heyderman, 1978;
Bosman et al., 1980) and rarely in "ordinary
lization of HCG in some seminomas has seminoma cells" (Morgan et al., 1982).
)ns for their histological classification and In agreement with previous workers (Heyderman,
,ourse. This study is based on a retro- 1978; Bosman et al., 1980; Morgan et al., 1982;
series of patients who presented between Morinaga et al., 1983) HCG was localised
1972. Consequently it was not possible to predominantly in typical syncytiotrophoblastic
the presence of HCG-containing cells with giant cells and in tumour giant cells or mulberry
g levels of HCG, the routine measurement cells and mononuclear seminoma cells. This
,h is a more recent development. provides evidence both for a link between different
ally, treatment and staging procedures germ cell tumours and the contention that
(3 (181) (169) (150) (122) HCG-VE (60)HCG LOCALIZATION IN SEMINOMA 477
teratomatous elements may develop from seminoma
cells.
The relevance of the morphological identification
of HCG-producing cells to the histopathologist and
clinician is apparent from the finding that
seminomas with cells containing HCG form a
group with a significantly worse prognosis.
Therefore, it is important that these elements can
be identified accurately. It is clear in this series that
even in a review of H & E sections aimed at
assessing the incidence of SGC, these cells will be
missed in a high proportion of cases even by an
experienced pathologist. These data indicate that
the localisation of HCG by immunocytochemistry
should form part of the routine assessment of
seminoma.
Incidence
This is the first large series in which the incidence
of HCG-containing cells in seminomas is described,
the only other comparable series being that of
Bosman et al. (1980), who found an incidence of
3/46 (7%). In other publications it is not clear
whether all seminomas have been investigated
immunocytochemically or whether this technique
has been restricted to those tumours in which
syncytiotrophoblasts have been seen on H & E
stained sections (Hedinger et al., 1979) or those
associated with elevated serum levels of HCG
(Javadpour et al., 1978).
In 228 seminomas 14.5% were found to contain
HCG positive cells. This figure is within the range
of published data based on morphological
appearances or HCG production. Since, as shown
in Table II, a relationship between the number of
sections and the HCG positive cells found could
not be demonstrated, it is unlikely that sampling
error was a problem in this series. However, some
bias may have been present in this series for three
reasons. Firstly, only tumours from which wax-
embedded material was available were examined.
Secondly, this material was obtained from a
Testicular Tumour Panel and the possibility exists
that "unusual" cases, such as those containing
SGC, were selectively referred. Thirdly, only four
P3 tumours were available, the remaining 224 being
of pathological stages P1 and P2.
Prognostic significance
The prognostic implication of HCG-containing cells
in seminomas has not been established (Javadpour
et al., 1978; Hedinger et al., 1979; Mostofi, 1980;
Bosman et al., 1980). Differences in mortality rates
for patients with and without tumour giant cells in
Thackray & Crane's (1976) series did not reach
statistical significance. In contrast, Mostofi (1980)
found a death rate of 7% in patients whose
tumours did not contain syncytiotrophoblastic cells
and 28% mortality of those whose tumours did
contain such cells.
The presence of syncytiotrophoblastic cells in
seminomas has been associated with elevated levels
of urinary chorionic gonadotrophin and a worse
prognosis (Dixon & Moore, 1952; Wilson &
Woodhead, 1972; Maier & Sulak, 1973). However,
this approach does not differentiate the influence of
disease bulk from the presence of HCG-producing
cells. The development of a serum fi-HCG radio-
immunoassay provided a more sensitive means for
detecting this protein. Elevated levels of serum p-
HCG have been found in 5-33% of patients with
seminoma (Cochran et al., 1975; Bartsch et al.,
1979; Javadpour, 1980, 1983) but there is still no
concensus as to its prognostic significance. Lange et
al. (1980) suggest that this finding in association
with metastatic seminoma is a poor prognostic sign
and indicates the use of chemotherapy. A further
clinical concern is that elevated HCG associated
with seminoma might be related to classical tropho-
blastic tumour or choriocarcinoma missed by the
sampling for histopathology.
The classification of tumours containing syncytio-
trophoblasts as seminomas rather than combined
tumours is inconsistent, as such cells constitute a
teratomatous element. In addition, the natural
history of seminomas with HCG-containing cells in
this historical study was in two respects similar to
that of combined tumours. Firstly, 23% of the
patients with HCG-containing tumours were
dead of their disease within 2 years of orchidec-
tomy, compared with only 8% of the patients
with tumours lacking this feature (P<0.01).
Secondly, late relapse was not observed in the
HCG-positive group, whereas 8/22 of the HCG-
negative group died of their disease during the
period 2-10 years following orchidectomy. In con-
trast to seminomas, late relapse is rarely encoun-
tered with teratomas. The clinical implication
of these data is that seminomas containing
HCG-positive cells might benefit more from treat-
ment regimes used for non-seminomatous testicular
germ cell tumours than those used for seminomas.
We wish to thank Professor K. Bagshawe for providing
the HCG antiserum. The cases reviewed here were
obtained from the British Testicular Tumour Registry.478 D.N. BUTCHER et al.
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